- Home
- ACRE vs XGN Comparison
ACRE vs XGN Comparison
Compare ACRE & XGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRE
- XGN
- Stock Information
- Founded
- ACRE 2011
- XGN 2002
- Country
- ACRE United States
- XGN United States
- Employees
- ACRE N/A
- XGN N/A
- Industry
- ACRE Real Estate Investment Trusts
- XGN Medical Specialities
- Sector
- ACRE Real Estate
- XGN Health Care
- Exchange
- ACRE Nasdaq
- XGN Nasdaq
- Market Cap
- ACRE 242.6M
- XGN 253.9M
- IPO Year
- ACRE 2012
- XGN 2019
- Fundamental
- Price
- ACRE $4.63
- XGN $11.91
- Analyst Decision
- ACRE Hold
- XGN Strong Buy
- Analyst Count
- ACRE 5
- XGN 6
- Target Price
- ACRE $4.83
- XGN $12.83
- AVG Volume (30 Days)
- ACRE 368.7K
- XGN 280.3K
- Earning Date
- ACRE 11-06-2025
- XGN 11-04-2025
- Dividend Yield
- ACRE 12.93%
- XGN N/A
- EPS Growth
- ACRE N/A
- XGN N/A
- EPS
- ACRE N/A
- XGN N/A
- Revenue
- ACRE $80,674,000.00
- XGN $58,862,000.00
- Revenue This Year
- ACRE N/A
- XGN $22.50
- Revenue Next Year
- ACRE N/A
- XGN $14.19
- P/E Ratio
- ACRE N/A
- XGN N/A
- Revenue Growth
- ACRE 58.54
- XGN 3.89
- 52 Week Low
- ACRE $3.35
- XGN $2.38
- 52 Week High
- ACRE $7.49
- XGN $12.23
- Technical
- Relative Strength Index (RSI)
- ACRE 50.50
- XGN 69.12
- Support Level
- ACRE $4.41
- XGN $11.58
- Resistance Level
- ACRE $4.76
- XGN $11.85
- Average True Range (ATR)
- ACRE 0.13
- XGN 0.34
- MACD
- ACRE 0.02
- XGN 0.00
- Stochastic Oscillator
- ACRE 63.16
- XGN 77.93
About ACRE Ares Commercial Real Estate Corporation
Ares Commercial Real Estate Corp is a specialty finance company and a Real Estate Investment Trust providing commercial real estate loans and related investments. It operates in one segment namely originating and managing a diversified portfolio of CRE debt-related investments. The group recognizes its revenues through the interest income it receives from loans.
About XGN Exagen Inc.
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.